AstraZeneca: Brilinta reduces risks, Phase III shows

(CercleFinance.com) - AstraZeneca's Brilinta significantly reduces cardiovascular events and coronary death beyond one year in heart attack survivors, the Anglo-Swedish pharma group said this Wednesday.


A new sub-analysis of a Phase III trial demonstrated a 19% reduction in risk in MACE (the composite of CV death, myocardial infarction, or stroke) and a 36% reduction in risk of coronary death from treatment with Brilinta in combination with low-dose aspirin, in people who had survived a heart attack and had stenosis (abnormal narrowing) in two or more coronary blood vessels, a condition known as multi-vessel disease.

Copyright (c) 2018 CercleFinance.com. All rights reserved.